hotspot -WSS

hotspot

author：comprehensive 2025-10-01 11:46:46 - browse：1888

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Eight reasons why you should get an updated Covid vaccine

WSS

Headspace, Meta partner to launch VR meditation app for Quest

Amylyx ALS drug failure raises questions and concerns

European regulators consider appeal over Amylyx ALS drug

First medicine developed to treat MASH expected to be approved soon

Readout LOUD podcast: Merger Mondays, Ozempic panic

Female surgeons have lower rates of long

knowledge

hotspot

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Cancer cells are shown to suck energy source from immune cells

Heart attack and stroke risk calculators need revising

First medicine developed to treat MASH expected to be approved soon

How one medical school became remarkably diverse

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

United colonoscopy coverage change 'may cost lives,' doctors say

Eight reasons why you should get an updated Covid vaccine

What does generative AI mean for health care? We asked experts

RSV shot was 90% effective at preventing hospitalizations in kids

knowledge

Sen. Paul opposes bill to ban Chinese biotechs

European regulators consider appeal over Amylyx ALS drug

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout LOUD podcast: Merger Mondays, Ozempic panic

STAT Readout: Today's biotech news includes Sana and Amylyx

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

Wikipedia

knowledge

focus